TheraRadar
← Back
Data updated: Mar 29, 2026

Eli Lilly

LLY
MetabolicOncologyImmunology
Big Pharma

Indianapolis-based pharma with leading positions in diabetes (Mounjaro, Trulicity) and Alzheimer's (Donanemab). Fast-growing obesity franchise with Zepbound.

$41.3B
Revenue (2024)
$750.0B
Market Cap
-
Trials
148
Approved (2yr)

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 44%
14 drugs Phase 3: 94 Phase 2: 30 Phase 1: 104
Oncology 19%
6 drugs Phase 3: 22 Phase 2: 29 Phase 1: 92
Immunology 17%
2 drugs Phase 3: 42 Phase 2: 25 Phase 1: 19
Neurology 11%
2 drugs Phase 3: 24 Phase 2: 12 Phase 1: 18
Dermatology 9%
3 drugs Phase 3: 24 Phase 2: 5 Phase 1: 6

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...